NO20200873A1 - Stabil krystall av 4-oxoquinolinforbindelse - Google Patents

Stabil krystall av 4-oxoquinolinforbindelse

Info

Publication number
NO20200873A1
NO20200873A1 NO20200873A NO20200873A NO20200873A1 NO 20200873 A1 NO20200873 A1 NO 20200873A1 NO 20200873 A NO20200873 A NO 20200873A NO 20200873 A NO20200873 A NO 20200873A NO 20200873 A1 NO20200873 A1 NO 20200873A1
Authority
NO
Norway
Prior art keywords
stable crystal
oxoquinoline compound
oxoquinoline
compound
crystal
Prior art date
Application number
NO20200873A
Other languages
English (en)
Inventor
Koji Ando
Motohide Satoh
Takahisa Motomura
Takashi Matsuda
Kentaro Kondo
Koji Matsuda
Shuji Miyake
Hideto Uehara
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35079161&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20200873(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Publication of NO20200873A1 publication Critical patent/NO20200873A1/no
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
NO20200873A 2004-05-20 2020-08-04 Stabil krystall av 4-oxoquinolinforbindelse NO20200873A1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004150979 2004-05-20
PCT/JP2005/009604 WO2005113508A1 (en) 2004-05-20 2005-05-19 Stable crystal of 4-oxoquinoline compound

Publications (1)

Publication Number Publication Date
NO20200873A1 true NO20200873A1 (no) 2007-02-07

Family

ID=35079161

Family Applications (6)

Application Number Title Priority Date Filing Date
NO20065790A NO339223B1 (no) 2004-05-20 2006-12-14 Stabil krystall av 4-oksoquinolinforbindelse
NO20161297A NO20161297A1 (no) 2004-05-20 2016-08-12 Stabil krystall av 4-oxoquinolinforbindelse
NO20190051A NO20190051A1 (no) 2004-05-20 2019-01-15 Stabil krystall av 4-oxoquinolinforbindelse
NO20200873A NO20200873A1 (no) 2004-05-20 2020-08-04 Stabil krystall av 4-oxoquinolinforbindelse
NO20220690A NO20220690A1 (no) 2004-05-20 2022-06-17 Stabil krystall av 4-oxoquinolinforbindelse
NO20230913A NO347902B1 (no) 2004-05-20 2023-08-25 Farmasøytisk sammensetning

Family Applications Before (3)

Application Number Title Priority Date Filing Date
NO20065790A NO339223B1 (no) 2004-05-20 2006-12-14 Stabil krystall av 4-oksoquinolinforbindelse
NO20161297A NO20161297A1 (no) 2004-05-20 2016-08-12 Stabil krystall av 4-oxoquinolinforbindelse
NO20190051A NO20190051A1 (no) 2004-05-20 2019-01-15 Stabil krystall av 4-oxoquinolinforbindelse

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20220690A NO20220690A1 (no) 2004-05-20 2022-06-17 Stabil krystall av 4-oxoquinolinforbindelse
NO20230913A NO347902B1 (no) 2004-05-20 2023-08-25 Farmasøytisk sammensetning

Country Status (33)

Country Link
US (6) US7635704B2 (no)
EP (4) EP2514746A1 (no)
JP (1) JP3754064B2 (no)
KR (1) KR20080064909A (no)
CN (1) CN1956961B (no)
AR (2) AR049280A1 (no)
AU (1) AU2005245296B2 (no)
BR (1) BRPI0510114B8 (no)
CA (1) CA2566922C (no)
CY (1) CY1113010T1 (no)
DK (2) DK3281939T3 (no)
ES (2) ES2388441T3 (no)
FI (2) FI3281939T3 (no)
FR (1) FR23C1040I1 (no)
HK (1) HK1083341A1 (no)
HR (2) HRP20231588T3 (no)
HU (2) HUE064615T2 (no)
IL (1) IL179250A0 (no)
LT (1) LT3281939T (no)
LU (1) LUC00334I2 (no)
MX (1) MXPA06013405A (no)
MY (1) MY134672A (no)
NO (6) NO339223B1 (no)
NZ (1) NZ551839A (no)
PE (2) PE20060358A1 (no)
PL (2) PL3281939T3 (no)
PT (2) PT1636190E (no)
RS (2) RS64845B1 (no)
RU (1) RU2330845C1 (no)
SI (2) SI1636190T1 (no)
TW (1) TWI329015B (no)
WO (1) WO2005113508A1 (no)
ZA (1) ZA200610647B (no)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6891227B2 (en) 2002-03-20 2005-05-10 International Business Machines Corporation Self-aligned nanotube field effect transistor and method of fabricating same
DK1564210T5 (da) * 2002-11-20 2010-05-03 Japan Tobacco Inc 4-Oxoquinolinforbindelser og anvendelse deraf som HIV-integraseinhibitorer
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2007063869A1 (ja) * 2005-11-30 2007-06-07 Japan Tobacco Inc. 高純度キノロン化合物の製造方法
AU2013203476C1 (en) * 2005-12-30 2016-11-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
NZ569576A (en) * 2005-12-30 2011-09-30 Gilead Sciences Inc Methods for improving the pharmacokinetics of HIV integrase inhibitors
US20090233964A1 (en) * 2005-12-30 2009-09-17 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
JP2009525261A (ja) * 2006-02-01 2009-07-09 日本たばこ産業株式会社 レトロウイルス感染症の治療のための、６−（３−クロロ−２−フルオロベンジル）−１−［（２ｓ）−１−ヒドロキシ−３−メチルブタン−２−イル］−７−メトキシ−４−オキソ−１，４−ジヒドロキノリン−３−カルボン酸またはその塩の使用
WO2007092802A1 (en) * 2006-02-09 2007-08-16 Boehringer Ingelheim International Gmbh Method for treating hiv infection through co-administration of tipranavir and gs 9137
BRPI0708685B8 (pt) * 2006-03-06 2021-05-25 Japan Tobacco Inc composto de 4-oxoquinolina, seu uso e método para produção dos mesmos
US8420821B2 (en) 2006-03-06 2013-04-16 Japan Tobacco Inc. Process for production of 4-oxoquinoline compound
KR101636221B1 (ko) 2006-07-07 2016-07-04 길리애드 사이언시즈, 인코포레이티드 치료제의 약동학 특성의 모듈레이터
SG174787A1 (en) 2006-09-12 2011-10-28 Gilead Sciences Inc Process and intermediates for preparing integrase inhibitors
DK3150586T3 (da) 2007-02-23 2020-02-17 Gilead Sciences Inc Modulatorer af farmakokinetiske egenskaber af terapeutika
CN103356622A (zh) * 2007-06-29 2013-10-23 吉里德科学公司 治疗用组合物及其用途
NZ582086A (en) * 2007-06-29 2012-07-27 Gilead Sciences Inc Therapeutic compositions and the use thereof
AR068403A1 (es) * 2007-09-11 2009-11-18 Gilead Sciences Inc Proceso e intermediarios para la preparacion de inhibidores de integrasa
US10039718B2 (en) 2008-05-02 2018-08-07 Gilead Sciences, Inc. Use of solid carrier particles to improve the processability of a pharmaceutical agent
SG10201706215UA (en) 2009-02-06 2017-08-30 Gilead Sciences Inc Tablets for combination therapy
WO2010137032A2 (en) * 2009-05-14 2010-12-02 Matrix Laboratories Ltd. Novel polymorphic forms of elvitegravir and its pharmaceutically acceptable salts
WO2011004389A2 (en) * 2009-06-18 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of elvitegravir
CN102212032B (zh) * 2011-04-20 2013-07-31 复旦大学 一种5-羟基喹诺酮类衍生物及其制备方法和用途
KR101663436B1 (ko) 2012-07-06 2016-10-06 제넨테크, 인크. N-치환된 벤즈아미드 및 이의 사용 방법
WO2014022707A1 (en) 2012-08-03 2014-02-06 Gilead Sciences, Inc. Process and intermediates for preparing integrase inhibitors
CN103819402B (zh) * 2012-11-17 2016-03-30 上海迪赛诺化学制药有限公司 埃替拉韦中间体及其制备方法和应用
CN103864682B (zh) * 2012-12-18 2016-12-28 上海迪赛诺化学制药有限公司 一种制备iii型埃替拉韦晶体的方法
BR122015029881B1 (pt) 2012-12-21 2022-04-26 Gilead Sciences, Inc Compostos carbamoilpiridona policíclicos, composição farmacêutica que os compreende e seu uso farmacêutico
EP3019503B1 (en) 2013-07-12 2017-09-06 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their use for the treatment of hiv infections
NO2865735T3 (no) 2013-07-12 2018-07-21
CN105315203A (zh) * 2014-06-06 2016-02-10 上海迪赛诺化学制药有限公司 一种v型埃替拉韦晶体及其制备方法
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (no) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
TWI738321B (zh) 2014-12-23 2021-09-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
AU2016244035B2 (en) 2015-04-02 2018-11-01 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
CN106008195B (zh) * 2016-05-19 2018-08-03 绍兴文理学院 一种2，4-二氟-5-碘苯甲酸的制备方法
EP3984536A1 (en) * 2020-10-19 2022-04-20 Centre national de la recherche scientifique Inhibition of the hiv-1 replication by compounds directed against a new target of the viral cycle

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472859A (en) * 1966-11-01 1969-10-14 Sterling Drug Inc 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters
WO1998045269A1 (fr) * 1997-04-08 1998-10-15 Centre National De La Recherche Scientifique (Cnrs) Derives de quinoleines en tant qu'inhibiteurs de la vih integrase

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS567162B1 (no) 1970-09-14 1981-02-16
JPS4826772A (no) 1971-08-11 1973-04-09
JPS6450979A (en) 1987-08-21 1989-02-27 Hitachi Shipbuilding Eng Co Method for discriminating whistle sound
JPH0651229B2 (ja) 1989-07-31 1994-07-06 新日本製鐵株式会社 プラズマアーク溶接方法および装置
IL100555A (en) 1991-02-07 2000-08-31 Hoechst Marion Roussel Inc N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them
NO304832B1 (no) * 1992-05-27 1999-02-22 Ube Industries Aminokinolonderivater samt middel mot HIV
JP2993316B2 (ja) 1992-05-27 1999-12-20 宇部興産株式会社 アリール基又は複素芳香環基置換アミノキノロン誘導体及びエイズ治療剤
JPH06199835A (ja) 1993-01-08 1994-07-19 Hokuriku Seiyaku Co Ltd ８−ジフルオロメトキシキノリン−３−カルボン酸誘導体
JPH06271568A (ja) 1993-03-22 1994-09-27 Hokuriku Seiyaku Co Ltd ７−フェニルピペラジニルキノリン−３−カルボン酸誘導体
AU683569B2 (en) * 1994-07-18 1997-11-13 Sankyo Company Limited Trifluoromethylquinolinecarboxylic acid derivative
JP2930539B2 (ja) 1994-07-18 1999-08-03 三共株式会社 トリフルオロメチルキノリンカルボン酸誘導体
JPH0826772A (ja) 1994-07-22 1996-01-30 Sony Corp 融着用ガラス、その製造方法及び製造装置、並びに磁気ヘッドの製造方法
EP0892801B1 (en) 1996-04-12 2002-01-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Acridone-derived compounds useful as antineoplastic and antiretroviral agents
JP3776203B2 (ja) 1997-05-13 2006-05-17 第一製薬株式会社 Ｉｃａｍ−１産生阻害剤
GB9721964D0 (en) * 1997-10-16 1997-12-17 Pfizer Ltd Isoquinolines
US6399629B1 (en) 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
US6248739B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company Quinolinecarboxamides as antiviral agents
US6248736B1 (en) 1999-01-08 2001-06-19 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents
PE20011349A1 (es) * 2000-06-16 2002-01-19 Upjohn Co 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales
US6559145B2 (en) * 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
WO2002036734A2 (en) 2000-10-12 2002-05-10 Merck & Co., Inc. Aza-and polyaza-naphthalenyl ketones useful as hiv integrase inhibitors
DE60124577T2 (de) 2000-10-12 2007-09-27 Merck & Co., Inc. Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer
IL157638A0 (en) 2001-03-01 2004-03-28 Shionogi & Co Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity
JP2002293745A (ja) 2001-03-29 2002-10-09 St Marianna Univ School Of Medicine 慢性関節リウマチ治療剤
US20030138483A1 (en) * 2001-05-25 2003-07-24 Sergio Petriconi Soft elastic capsules and compositions thereof
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
FR2827600A1 (fr) 2001-07-20 2003-01-24 Lipha Derives acides de quinolone et leurs applications en therapeutique
JP4035765B2 (ja) 2002-10-31 2008-01-23 横河電機株式会社 フーリエ変換型赤外線分光計
JP3567162B1 (ja) 2002-11-20 2004-09-22 日本たばこ産業株式会社 ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
DK1564210T5 (da) * 2002-11-20 2010-05-03 Japan Tobacco Inc 4-Oxoquinolinforbindelser og anvendelse deraf som HIV-integraseinhibitorer
MY134672A (en) * 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
WO2005113509A1 (en) * 2004-05-20 2005-12-01 Japan Tobacco Inc. Novel 4-oxoquinoline compound and use thereof as hiv integrase inhibitor
JP4629104B2 (ja) * 2004-05-21 2011-02-09 日本たばこ産業株式会社 ４−オキソキノリン誘導体および抗ｈｉｖ剤を含む併用剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3472859A (en) * 1966-11-01 1969-10-14 Sterling Drug Inc 1-alkyl-1,4-dihydro-4-oxo-3 quinoline-carboxylic acids and esters
WO1998045269A1 (fr) * 1997-04-08 1998-10-15 Centre National De La Recherche Scientifique (Cnrs) Derives de quinoleines en tant qu'inhibiteurs de la vih integrase

Also Published As

Publication number Publication date
SI3281939T1 (sl) 2024-02-29
WO2005113508A1 (en) 2005-12-01
NO20161297A1 (no) 2007-02-07
AU2005245296A1 (en) 2005-12-01
EP3281939B1 (en) 2023-10-18
NO20230913A1 (no) 2007-02-07
CN1956961B (zh) 2010-05-26
ES2960824T3 (es) 2024-03-06
EP4299563A3 (en) 2024-02-28
BRPI0510114B8 (pt) 2021-05-25
CA2566922A1 (en) 2005-12-01
JP3754064B2 (ja) 2006-03-08
DK3281939T3 (da) 2024-01-22
RS64845B1 (sr) 2023-12-29
RS52375B (en) 2012-12-31
EP2514746A1 (en) 2012-10-24
FR23C1040I1 (fr) 2023-12-29
PL1636190T3 (pl) 2012-10-31
US20060030710A1 (en) 2006-02-09
PT3281939T (pt) 2023-11-22
ZA200610647B (en) 2008-06-25
HUS2400006I1 (hu) 2024-04-28
US20180029989A1 (en) 2018-02-01
KR20080064909A (ko) 2008-07-09
EP1636190A1 (en) 2006-03-22
MXPA06013405A (es) 2007-03-01
DK1636190T3 (da) 2012-09-24
ES2388441T3 (es) 2012-10-15
PT1636190E (pt) 2012-08-20
FI3281939T3 (fi) 2023-10-23
RU2330845C1 (ru) 2008-08-10
HRP20231588T3 (hr) 2024-03-15
AR049280A1 (es) 2006-07-12
NO20220690A1 (no) 2007-02-07
AR096100A2 (es) 2015-12-09
AU2005245296B2 (en) 2010-08-12
EP4299563A2 (en) 2024-01-03
NO347902B1 (no) 2024-05-06
EP3281939A1 (en) 2018-02-14
EP1636190B1 (en) 2012-06-27
TWI329015B (en) 2010-08-21
HK1083341A1 (en) 2006-06-30
HUE064615T2 (hu) 2024-04-28
CN1956961A (zh) 2007-05-02
LUC00334I2 (no) 2024-07-01
SI1636190T1 (sl) 2012-09-28
NZ551839A (en) 2009-11-27
PE20120361A1 (es) 2012-05-03
US20220235009A1 (en) 2022-07-28
FIC20240008I1 (fi) 2024-03-20
MY134672A (en) 2007-12-31
NO339223B1 (no) 2016-11-21
JP2006001927A (ja) 2006-01-05
CY1113010T1 (el) 2016-04-13
IL179250A0 (en) 2007-03-08
US7635704B2 (en) 2009-12-22
LT3281939T (lt) 2023-11-27
US20100204271A1 (en) 2010-08-12
TW200600097A (en) 2006-01-01
US20150361044A1 (en) 2015-12-17
BRPI0510114B1 (pt) 2020-09-15
HRP20120681T1 (hr) 2012-09-30
PL3281939T3 (pl) 2024-03-18
US8981103B2 (en) 2015-03-17
NO20065790L (no) 2007-02-07
US20190185433A1 (en) 2019-06-20
CA2566922C (en) 2011-01-11
PE20060358A1 (es) 2006-05-12
BRPI0510114A (pt) 2007-09-25
NO20190051A1 (no) 2007-02-07

Similar Documents

Publication Publication Date Title
NO20220690A1 (no) Stabil krystall av 4-oxoquinolinforbindelse
DK1778618T3 (da) Syntese af triethylentetraminer
DK2377869T3 (da) Syntese af Bortezomib
DE602005012267D1 (de) N von geräten
DE602006004463D1 (de) Kristallform von asenapinmaleat
ATE521238T1 (de) Kristalline modifikationen des pyraclostrobins
FI20050853A0 (fi) Käyttäjädatan hallinta
DK1737304T3 (da) Flydende koncentreret formel
DE602005009127D1 (de) Siliziumverbindung
DK1917227T3 (da) Krystalformer af astaxanthin
DE602005009017D1 (de) Substituierte n-sulfonylaminobenzyl-2-phenoxyacetamidverbindungen
NO20055643D0 (no) Preparation of lodixanol
IS8470A (is) Notkun lífrænna efnasambanda
CR9144A (es) Formulaciones de benzoxazoles sustituidos
NO20043305D0 (no) Preparation of lodixanol
NO20070299L (no) Novel heterocyclic compounds
IS7963A (is) Efnasambönd með hamlandi virkni gegn prólýlólígópeptíðasa
DK1656358T3 (da) Stabil polymorf af bifeprunox-mesilat
DK1730109T3 (da) Syntese af pyrrol-2-carbonitriler
ATE384719T1 (de) Dioxazinyl-substituierte thienylsulfonylaminocarbonylverbindungen
SE0402103D0 (sv) Novel compounds
SE0400331L (sv) Fiskerulle av multiplikatortyp
SE0403161D0 (sv) Ny användning av glucosine
ITVR20040028A1 (it) Struttura di longherone
FI20041228A (fi) Hiomakiven kunto

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: JAPAN TOBACCO INC., JP

FC2A Withdrawal, rejection or dismissal of laid open patent application